Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s40139-017-0123-0 http://scihub22266oqcxt.onion/10.1007/s40139-017-0123-0 C5613763!5613763!28966883     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Pathobiol+Rep 2017 ; 5 (1): 35-42 Nephropedia Template TP {{tp|p=28966883|t=2017. MicroRNAs in Cancer: challenges and opportunities in early detection, disease monitoring, and therapeutic agents |pdf=|usr=}}{{28966883}} gab.com Text MicroRNAs in Cancer: challenges and opportunities in early detection, disease monitoring, and therapeutic agents JO: Curr Pathobiol Rep http://www.kidney.de/pget.php?&tw=1&pmid=28966883 #FOAvip Purpose of review: The goals of this review are to examine the usefulness of miRNAs as diagnostic and prognostic biomarkers for cancer and to evaluate the applicability of miRNAs as cancer therapeutics. Recent findings: Examination of miRNA milieu from body fluids offers a new alternative for quick, affordable and easy analysis of disease status in patients. Blood-based exosomal miRNAs have increased stability and are an excellent choice for clinical cancer diagnostics and prognostics. Currently, there are many miRNA signatures associated with cancer and progression but there is no consensus among multiple sera and tumor sample studies. Off-target and immunological effects remains an obstacle for use of miRNAs as novel chemotherapeutics in the clinic. Recent developments in nanotechnology and drug delivery systems which target the tumor microenvironment may provide an alternative therapeutic approach with decreased toxicity. Summary: This review critically evaluates the literature investigating the use of miRNAs as biomarkers and their future as potential therapeutics. Twit Text FOAVip MicroRNAs in Cancer: challenges and opportunities in early detection, disease monitoring, and therapeutic agents ????Curr Pathobiol Rep http://www.kidney.de/pget.php?&tw=1&pmid=28966883 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28966883 #FOAvip English Wikipedia <ref>{{Cite pmid|28966883}}</ref> MicroRNAs in Cancer: challenges and opportunities in early detection, disease monitoring, and therapeutic agents #MMPMID28966883 Chatterjee N; Rana S; Espinosa-Diez C; Anand S Curr Pathobiol Rep 2017[Mar]; 5 (1): 35-42 PMID28966883show ga Purpose of review: The goals of this review are to examine the usefulness of miRNAs as diagnostic and prognostic biomarkers for cancer and to evaluate the applicability of miRNAs as cancer therapeutics. Recent findings: Examination of miRNA milieu from body fluids offers a new alternative for quick, affordable and easy analysis of disease status in patients. Blood-based exosomal miRNAs have increased stability and are an excellent choice for clinical cancer diagnostics and prognostics. Currently, there are many miRNA signatures associated with cancer and progression but there is no consensus among multiple sera and tumor sample studies. Off-target and immunological effects remains an obstacle for use of miRNAs as novel chemotherapeutics in the clinic. Recent developments in nanotechnology and drug delivery systems which target the tumor microenvironment may provide an alternative therapeutic approach with decreased toxicity. Summary: This review critically evaluates the literature investigating the use of miRNAs as biomarkers and their future as potential therapeutics. äMicroRNAs in Cancer: challenges and opportunities in early detection, (epmc).pdf DeepDyve Pubget Overpricing